We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $87.85 · 26 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Why BioMarin Pharmaceutical (BMRN) stock is trading up today - MSN
Why BioMarin Pharmaceutical (BMRN) stock is trading up today MSN
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development Yahoo Finance
Kim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities - BioMarin Pharmaceutical
Kim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities BioMarin Pharmaceutical
Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria - BioMarin Pharmaceutical
Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria BioMarin Pharmaceutical
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - simplywall.st
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 03. | After market close (AMC) | $0.96 | — | — | $934.49M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.95 | — | — | $745.15M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $1.56 | — | — | $2.11B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.01 | — | — | $1.36B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 23. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 20. | B of A Securities | — | Maintain | Buy → Buy | — | B of A Securities: Buy |
| 2026. 05. 19. | Citigroup | — | Initiate coverage | — → Buy | — | Citigroup: Buy |
| 2026. 05. 18. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
| 2026. 05. 08. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 06. | Bernstein | — | Maintain | Outperform → Outperform | — | Bernstein: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,199,206 | $67.74B | 0.12% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 438,817 | $26.08B | 0.04% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 69,766 | $4.15B | 0.01% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 44,475 | $2.51B | 0.00% | — | New position |